Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.54 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 4/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17451629 | 1.00 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1GSR | |
| SCHEMBL2234222 | 0.95 | OTC (0.54) | DPP7GNAI3GNAO1GNAI1GSR | |
| SCHEMBL2234214 | 0.95 | OTC (0.54) | DPP7GNAI3GNAO1GNAI1GSR | |
| SCHEMBL20085606 | 0.89 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1GSR | |
| SCHEMBL19738538 | 0.88 | DPP7 (0.53) | DPP7GNAI3GNAO1GNAI1GSR | |
| SCHEMBL5666448 | 0.88 | DPP7 (0.53) | DPP7GNAI3GNAO1GNAI1GSR | |
| SCHEMBL1768888 | 0.87 | GSR (0.43) | DPP7GSROTCCYP2D6CYP2C9 | |
| SCHEMBL1768887 | 0.87 | GSR (0.43) | DPP7GSROTCCYP2D6CYP2C9 | |
| SCHEMBL22689723 | 0.86 | DPP7 (0.51) | DPP7GNAI3GNAO1GNAI1GSR | |
| SCHEMBL22689791 | 0.86 | DPP7 (0.51) | DPP7GNAI3GNAO1GNAI1GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | claimed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | claimed |
| US-20250327074-A1 | THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS | SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4090670-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | disclosed |
| US-10221309-B2 | Latex functionalized with structural units of an amino acid | ROHM AND HAAS COMPANY (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180086909-A1 | LATEX FUNCTIONALIZED WITH STRUCTURAL UNITS OF AN AMINO ACID | ROHM AND HAAS COMPANY | 2018-03-29 | — | — | US | disclosed |
| EP-3299400-A1 | LATEX FUNCTIONALIZED WITH STRUCTURAL UNITS OF AN AMINO ACID | Rohm and Haas Company (US) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP7 358/4885GNAI3 551/4885GNAO1 3649/4885 |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | DPP7 161/4885GNAI3 372/4885GNAO1 365/4885 |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP7 358/4885GNAI3 551/4885GNAO1 3649/4885 |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP7 358/4885GNAI3 551/4885GNAO1 3649/4885 |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | DPP7 161/4885GNAI3 372/4885GNAO1 365/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | DPP7 358/4885GNAI3 551/4885GNAO1 3649/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP7 358/4885GNAI3 551/4885GNAO1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.